Why Moderna is seeking Authorization From U.S. FDA & Global Regulators ?

Moderna, Inc. (NASDAQ: MRNA) said on May 25 that a clinical study of its COVID-19 vaccine mRNA-1273 showed 100 percent effectiveness in the 12 to 17 years age group. Moderna CEO Stéphane Bancel said the company would submit the study data to the U.S. Food and Drug Administration and other regulators globally in early June and seek authorization. The Massachusetts-based biotechnology company’s stock rose around 2 percent to US$167.34 when the market opened for trading on Tuesday.

The Centre for Disease Control and Prevention (CDC), coordinating the covid response, said only a few kids compared to adults get infected with SARS-CoV-2, but they can still become sick and spread the virus. Vaccinating children is considered crucial for herd immunity. Moderna said the mRNA-1273 met its primary immunogenicity endpoint and the safety and tolerability profile was consistent with the Phase 3 study in adults. No cases of COVID-19 were found in participants who were administered with two shots, while four children who received the placebo were found positive.

Earlier in May, the FDA gave Emergency Use Authorization for Pfizer - BioNTech’s covid vaccine for 12 to 15 years old in the U.S. The vaccine, jointly developed by Pfizer and Germany’s BioNTech, showed 100 percent effectiveness.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business